MetaCap

BioVie (BIVI) vs Palatin Technologies (PTN)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

BioVie (BIVI) has outperformed Palatin Technologies (PTN) over the past year, losing 38.2% versus a loss of 79.9%. Over five years, PTN leads with a -99.3% price change compared with -99.9% for BIVI. BioVie is the larger company by market cap ($8.6 million vs $8.2 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BIVI-38.22%PTN-79.93%
+84%-2%-88%
Nov 21, 20251 yearNov 20, 2026
BIVI-99.86%PTN-98.98%
+138%+13%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BIVI versus PTN key metrics
MetricBIVIPTN
Share price$0.80$4.58
Market cap$8.58M$8.16M
1-day change-12.07%-7.10%
YTD return-31.03%-70.22%
1-year return-38.22%-79.93%
5-year return-99.87%-99.35%
EPS (TTM)$-2.85$-2.96
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$8.83M
Net income (latest FY)$-22.07M$-8.38M
Operating margin—-98.17%
Net margin—-94.88%
52-week high$3.79$31.00
52-week low$0.7515$4.51
Distance from 52-week high-78.89%-85.23%
Analyst consensusnonestrong_buy
Avg. price target upside+557.50%+1068.12%
Average volume568.61K71.93K
Shares outstanding10.72M1.78M
Employees1325
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BIVI has outperformed PTN by 41.7 percentage points over the past year.

About BioVie

BIVI stock →

BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 3 for the treatment of life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees

About Palatin Technologies

PTN stock →

Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity completed Phase 2 clinical trial; completed a phase 2 of diabetic nephropathy It also provides pl9643 for dry eye disease; and oral PL8177 for inflammatory bowel diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees

BIVI vs PTN FAQ

Which is bigger, BioVie or Palatin Technologies?

BioVie (BIVI) is larger, with a market capitalization of $8.58M compared with $8.16M for Palatin Technologies (PTN).

Which stock has performed better over the past year, BIVI or PTN?

BIVI returned -38.22% over the past 12 months, compared with -79.93% for PTN (price return, excluding dividends). Past performance does not predict future results.

Are BioVie and Palatin Technologies in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons